Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 182 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aspirin (ASA) placebo Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee

NCT02068599
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TV-45070, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
42
States / cities
Anaheim, California • Cerritos, California • El Cajon, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 13, 2026, 2:55 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Aspirin and Plavix Following Coronary Artery Bypass Grafting

NCT01158703
View directory record Official record
Conditions
Coronary Graft Patency
Interventions
clopidogrel, sugar pill, Aspirin
Drug
Lead sponsor
Ahmad Slim
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 13, 2026, 2:55 PM EDT
Completed No phase listed Observational Results available

TAXUS Libertē Post Approval Study

NCT00997503
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté Paclitaxel-Eluting Coronary Stent, prasugrel, placebo, aspirin
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
4,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
82
States / cities
Mesa, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

NCT04066725
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Aspirin 81 mg, Aspirin 325mg, Placebo oral tablet
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 13, 2026, 2:55 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

NCT02521285
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 13, 2026, 2:55 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Sleep and Inflammatory Resolution Pathway

NCT03377543
View directory record Official record
Conditions
Inflammatory Response, Inflammation, Sleep, Sleep Restriction
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Not applicable Interventional Results available

The ARIES HeartMate 3 Pump IDE Study

NCT04069156
View directory record Official record
Conditions
Heart Failure
Interventions
LVAD Implant, Aspirin 100mg, Placebo oral tablet
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 13, 2026, 2:55 PM EDT
Recruiting Phase 4 Interventional

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

NCT06468202
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Aspirin 81 mg, Aspirin 162 mg
Drug
Lead sponsor
Ohio State University
Other
Eligibility
14 Years to 35 Years · Female only
Enrollment
10,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 13, 2026, 2:55 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction

NCT01047722
View directory record Official record
Conditions
Healthy
Interventions
Aspirin ingestion followed by doing a Bleeding Volume Test, Gatorade Placebo followed by Bleeding Volume Test.
Drug · Procedure
Lead sponsor
Klein, Jeffrey A., M.D.
Individual
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Newport Beach, California • San Juan Capistrano, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 13, 2026, 2:55 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Early Prevention of Preeclampsia Study

NCT01547390
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 13, 2026, 2:55 PM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency

NCT03008915
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, Emphysema, Chronic Obstructive Pulmonary Disease
Interventions
Aspirin, Placebo, Withdrawal from alpha1 antitrypsin replacement therapy
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Thromboxane Function in Women With Endometriosis

NCT05962034
View directory record Official record
Conditions
Endometriosis
Interventions
Aspirin, Placebo
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 13, 2026, 2:55 PM EDT
Terminated Phase 3 Interventional Results available

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

NCT04498273
View directory record Official record
Conditions
COVID-19
Interventions
Apixaban 2.5 MG, Apixaban 5MG, Aspirin, Placebo
Drug
Lead sponsor
Frank C Sciurba
Other
Eligibility
40 Years to 80 Years
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
71
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

NCT00983580
View directory record Official record
Conditions
Adenomatous Polyp
Interventions
Aspirin, Eflornithine, Laboratory Biomarker Analysis, Placebo, Telephone-Based Intervention
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

NCT02239120
View directory record Official record
Conditions
Stroke, Secondary Prevention
Interventions
optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 150 Years
Enrollment
5,390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
110
States / cities
Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biosynthesis of PGD2 in Vivo

NCT01275300
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Aspirin, Placebo, Niacin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 13, 2026, 2:55 PM EDT
Terminated Phase 3 Interventional Results available

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

NCT02313909
View directory record Official record
Conditions
Stroke
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
7,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
38
States / cities
Tucson, Arizona • Long Beach, California • Stanford, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Body Weight, Aspirin Dose and Pro-resolving Mediators

NCT04697719
View directory record Official record
Conditions
Body Weight
Interventions
Aspirin 81mg, Aspirin 325mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Phase 4 Interventional

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhanced Firefighter Rehab Trial: The Role of Aspirin in Preventing Heat Stress Induced Platelet Activation

NCT01066923
View directory record Official record
Conditions
Heat Stress Disorders
Interventions
Daily aspirin (ASA), Active cooling, Acute aspirin (ASA), Passive cooling, Daily placebo, Acute placebo
Drug · Other
Lead sponsor
Dave Hostler
Other
Eligibility
18 Years to 49 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Aspirin on Gut Microbiome

NCT02761486
View directory record Official record
Conditions
Healthy
Interventions
Aspirin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 13, 2026, 2:55 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Timed Aspirin Chronobiome Study

NCT03590821
View directory record Official record
Conditions
Healthy
Interventions
Aspirin 81 mg, Celecoxib 200mg capsule
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 13, 2026, 2:55 PM EDT
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 13, 2026, 2:55 PM EDT